Hookipa Pharma Inc (HOOK)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jörn Aldag
Employees:
160
430 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY 10016
0114318906360

HOOKIPA Pharma Inc. develops immunotherapeutics targeting infectious diseases and cancers. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.

Data derived from most recent annual or quarterly report
Market Cap 85.466 Million Shares Outstanding50.873 Million Avg 30-day Volume 291.38 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.05
Price to Revenue8.5457 Debt to Equity0.0348 EBITDA-70.884 Million
Price to Book Value0.843 Operating Margin-566.3994 Enterprise Value-11.54 Million
Current Ratio5.478 EPS Growth-0.212 Quick Ratio4.532
1 Yr BETA 1.4505 52-week High/Low 7.3 / 1.25 Profit Margin-523.5403
Operating Cash Flow Growth-7.0331 Altman Z-Score-0.4972 Free Cash Flow to Firm -52.648 Million
View SEC Filings from HOOK instead.

View recent insider trading info

Hookipa Pharma Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding HOOK (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HOOK

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-07-01 by VAN DE WINKEL JAN
  • 4: filed on 2022-07-01 by REILLY TIMOTHY P.
  • 4: filed on 2022-07-01 by ORLINGER KLAUS
  • 4: filed on 2022-07-01 by O'NEILL JULIE
  • 4: filed on 2022-07-01 by NECINA ROMAN
  • 4: filed on 2022-07-01 by MATUSHANSKY IGOR
  • 4: filed on 2022-07-01 by KELLY MICHAEL AARON
  • 4: filed on 2022-07-01 by KAUFMAN DAVID ROSS
  • 4: filed on 2022-07-01 by KANDERA REINHARD
  • 4: filed on 2022-07-01 by BAKER CHRISTINE D.

    • Events (8k)

  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-01:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-06:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-24:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2022-03-01:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    O'NEILL JULIE

    • Director
    		 20,000 2022-06-30 1

    ALDAG JORN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 275,250 2022-06-30 3

    VAN DE WINKEL JAN

    • Director
    		 40,000 2022-06-30 1

    MATUSHANSKY IGOR CHIEF MEDICAL OFFICER

    • Officer
    		 92,950 2022-06-30 4

    KANDERA REINHARD CHIEF FINANCIAL OFFICER

    • Officer
    • Director
    		 92,950 2022-06-30 3

    ORLINGER KLAUS CHIEF SCIENTIFIC OFFICER

    • Officer
    		 48,350 2022-06-30 3

    KELLY MICHAEL AARON

    • Director
    		 20,000 2022-06-30 1

    KAUFMAN DAVID ROSS

    • Director
    		 20,000 2022-06-30 1

    NECINA ROMAN CHIEF TECHNOLOGY OFFICER

    • Officer
    		 48,350 2022-06-30 3

    BAKER CHRISTINE D. CHIEF OPERATING OFFICER

    • Officer
    		 100,000 2022-06-30 3

    REILLY TIMOTHY P.

    • Director
    		 40,000 2022-06-30 2

    GILEAD SCIENCES INC

    • 10% Owner
    		 3,759,465 2022-02-15 1

    SEGHEZZI GRAZIANO

    • Director
    		 No longer subject to file 2021-06-01 0

    LENGAUER CHRISTOPH

    • Director
    		 9,600 2021-06-01 0

    SORIA JEAN-CHARLES

    • Director
    		 9,600 2021-06-01 0

    SOFINNOVA CAPITAL VI FCPR

    SOFINNOVA PARTNERS SAS

    • 10% Owner
    		 3,177,574 2021-04-21 0

    VAN DEVENTER SANDER

    • Director
    		 2,485 2020-10-21 0

    LILJA ANDERS SR. VP, TECHNICAL DEVELOPMENT

    • Officer
    		 0 2020-01-23 0

    BAKER BROS. ADVISORS LP

    BAKER BROS. ADVISORS (GP) LLC

    BAKER FELIX

    BAKER JULIAN

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 No longer subject to file 2019-04-23 0

    FORBION CAPITAL FUND II COOPERATIEF U.A.

    • 10% Owner
    		 2,494,173 2019-04-23 0

    MORELAND MARK D CHIEF FINANCIAL OFFICER

    • Officer
    		 16,400 2011-11-21 0

    PASTORE V SEBASTIAN EVP, BREWING OPERATIONS & LOG

    • Officer
    		 43,600 2011-09-06 0

    LORD DAVID R

    • Director
    		 19,284 2011-08-26 0

    WALL MARTIN J IV VICE PRESIDENT, SALES

    • Officer
    		 1,597 2011-08-23 0

    CRAMER MARC J

    • Director
    		 3,894 2011-08-18 0

    MICHAELSON TERRY E CHIEF EXECUTIVE OFFICER

    • Officer
    		 25,299 2010-12-02 0

    KELLY KEVIN R

    • Director
    		 23,100 2009-04-06 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BAKER CHRISTINE D. - Officer CHIEF OPERATING OFFICER

    		2022-07-01 16:06:47 -0400 2022-06-30 A 100,000 a 100,000 direct

    KELLY MICHAEL AARON - Director

    		2022-07-01 16:09:41 -0400 2022-06-30 A 20,000 a 20,000 direct

    KAUFMAN DAVID ROSS - Director

    		2022-07-01 16:08:31 -0400 2022-06-30 A 20,000 a 20,000 direct

    O'NEILL JULIE - Director

    		2022-07-01 16:12:29 -0400 2022-06-30 A 20,000 a 20,000 direct

    NECINA ROMAN - Officer CHIEF TECHNOLOGY OFFICER

    		2022-07-01 16:11:31 -0400 2022-06-30 A 48,350 a 48,350 direct

    MATUSHANSKY IGOR - Officer CHIEF MEDICAL OFFICER

    		2022-07-01 16:11:01 -0400 2022-06-30 A 92,950 a 92,950 direct

    KANDERA REINHARD - Director - Officer CHIEF FINANCIAL OFFICER

    		2022-07-01 16:07:51 -0400 2022-06-30 A 92,950 a 92,950 direct

    VAN DE WINKEL JAN - Director

    		2022-07-01 16:15:25 -0400 2022-06-30 A 40,000 a 40,000 direct

    REILLY TIMOTHY P. - Director

    		2022-07-01 16:14:40 -0400 2022-06-30 A 40,000 a 40,000 direct

    ORLINGER KLAUS - Officer CHIEF SCIENTIFIC OFFICER

    		2022-07-01 16:13:31 -0400 2022-06-30 A 48,350 a 48,350 direct

    ALDAG JORN - Director - Officer CHIEF EXECUTIVE OFFICER

    		2022-07-01 16:05:57 -0400 2022-06-30 A 275,250 a 275,250 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    HOOKIPA PHARMA INC HOOK 2022-08-12 22:15:03 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 21:45:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 21:15:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 20:45:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 20:15:05 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 19:45:03 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 19:15:05 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 18:45:03 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 18:15:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 17:45:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 17:15:05 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 16:45:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 16:15:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 15:45:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 15:15:05 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 14:45:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 14:15:05 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 13:45:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 13:15:04 UTC -6.2828 8.6028 1200000
    HOOKIPA PHARMA INC HOOK 2022-08-12 12:45:04 UTC -6.2828 8.6028 1200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund HOOK -9000.0 shares, $-20520.0 2022-03-31 N-PORT

    Elevate your investments